



**An Expert Appraisal of the Latest Science and the Evolving Treatment Landscape in ATTR:
Achieving Outcomes Synergy at the Cardiologist-Neurologist Interface**

15 min	Characterizing the Fundamentals of ATTR: Epidemiology, Pathophysiology, Patient Burden, and the Intrinsic Heterogeneity of ATTR-CM, ATTR-PN, and ATTR of Mixed Phenotype <u>Learning Objective 1:</u> Describe the prevalence, multisystem pathophysiology, and heterogeneous clinical manifestations of ATTR, highlighting the clinical gravity of ATTR-CM, ATTR-PN, and ATTR of mixed phenotype. <u>Learning Objective #2:</u> Recognize the imperative need for early and accurate diagnosis of ATTR, irrespective of phenotype, as a means of facilitating the initiation of evidence-based treatment earlier in the disease arc.
25 min	Embracing a New Era in ATTR Disease Modification: The Established and Evolving Evidentiary Base for Novel Therapeutics Across the ATTR Continuum <u>Learning Objective #3:</u> Examine the novel pharmacologic mechanisms being investigated for ATTR, including inhibition of TTR synthesis, TTR stabilization, and TTR amyloid removal. <u>Learning Objective 4:</u> Evaluate the totality of emerging clinical trial evidence for novel therapeutics in ATTR-CM and ATTR-PN, with a focus on recent readouts, ongoing pivotal studies, and regulatory updates.
15 min	A Promising Glimpse of the Future: Early-Career Perspectives and Emerging ATTR Research from the 1st Annual ATTR Early-Career Research Forum <u>Learning Objective 5:</u> Discuss original ATTR research rationale, design, and data findings from work conducted by the winners of the 1st Annual ATTR Early-Career Research Forum.
20 min	Empowering ATTR Outcomes Optimization at the Cardiology-Neurology Nexus: A Case-Driven Practicum <u>Using real-world patient cases developed by expert faculty and tailored to the target audience</u> <u>Learning Objective 6:</u> Design individualized, evidence-driven treatment plans for patients with ATTR-CM and ATTR-PN, emphasizing cardiologist and neurologist roles in the multidisciplinary management of these conditions.
10 min	Interactive Expert Discussion and Audience Q&A

Release Date: November 14, 2025

Expiration Date: November 14, 2026

Accreditation



Physicians

- American Academy of CME, Inc., designates this enduring material for a maximum of 1.5 *AMA PRA Category 1 Credits*[™]. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nurse Practitioners and Nurses

- American Academy of CME, Inc., designates this educational activity for 1.5 ANCC contact hours (1.0 pharmacotherapeutic contact hours).

Other HCPs

- Other members of the care team will receive a certificate of participation.



JOINTLY ACCREDITED PROVIDER[™]
INTERPROFESSIONAL CONTINUING EDUCATION

In support of improving patient care, this activity has been planned and implemented by American Academy of CME, Inc. and Cornerstone Medical Education. American Academy of CME, Inc. is Jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

This activity is supported through an independent educational grant from AstraZeneca and Ionis Pharmaceuticals.

OUR EDUCATIONAL SOLUTION

This educational activity is targeted to cardiologists, neurologists, heart failure specialists, and the interprofessional team of nurse practitioners, physician assistants, and cardiac nurses that help manage patients with transthyretin-mediated amyloidosis (ATTR). Designed as both a data intensive and a case-based practicum, this enduring activity will offer learners an expert-led appraisal of the evolving clinical trial evidence and regulatory updates for novel therapeutics in ATTR, with an emphasis on clinical best practices for treatment selection and sequencing in ATTR-CM, ATTR-PN, and ATTR of mixed phenotype, and will include an intensive review of established and emerging pharmacologic mechanisms and incisively examine how they interface with ATTR pathophysiology. Attendees will also get a unique “glimpse beyond the cutting edge of the calculus” in a segment led by the two winners of the 1st Annual (2024) ATTR Early-Career Research Forum, in which they detail the rationale, design, results, and real-world promise of their original ATTR research projects. Finally, the session will be punctuated by an interactive and dynamic case-based discussion that not only engages cardiologists, neurologists, and other members of the ATTR multidisciplinary and interprofessional treatment team, but also incorporates the patient/caregiver voice in a responsive effort to bridge the disconnect between clinician and patient expectations, all with the overarching strategic goals of harmonizing shared decision-making, optimizing evidence-based treatment decisions, and ultimately, improving outcomes across the heterogeneous ATTR disease continuum.